Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Neidig, C., Teichmann, B., Harde, J., Trarbach, T., 2015.

Oncol Res Treat 38 (suppl.5)(P235), 70. doi:10.1159/000439070

Studie: PIAZA; Indikation: Hämoblastosen; Jahr: 2015; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com